Emerging disease‐modifying strategies targeting α‐synuclein for the treatment of Parkinson's disease

Parkinson's disease is the most common neurodegenerative movement disorder. It arises as a result of neuronal cell death in specific brain regions, notably the substantia nigra pars compacta, and is characterized by the accumulation of α‐synuclein in these brain regions. Current pharmacological therapies alleviate the motor symptoms of the disease and are particularly effective in the early stages of the disease. Ongoing drug development efforts focus on disease‐modifying strategies that aim to halt or slow disease progression. In this review, we explore a number of emerging disease‐modifying strategies with a focus on direct and indirect targeting of α‐synuclein dysfunction. We summarize newer classes of small molecules and biological agents intended to attenuate protein aggregation or to target enzymes that may increase the degradation of the pathogenic forms of α‐synuclein. Finally, we discuss emerging strategies that are demonstrating the potential for disease modification at the preclinical stage.